Drug-Addicted Oncology Practice: The Drug Test

Area of Science:

• Health economics
• Oncology practice management

Background:

• The buy-and-bill model has sustained oncology practices for over 30 years.
• Infusion services revenue significantly boosted practice finances, enabling care for vulnerable patients.
• High-cost drugs created financial distortions, leading to over-reliance on drug margins.

Purpose of the Study:

• To analyze the financial impact of the buy-and-bill model on oncology practices.
• To examine the consequences of government and payer interventions on practice revenue.
• To advise practices on financial sustainability beyond drug margins.

Main Methods:

• Analysis of financial trends in medical oncology practices.
• Review of the effects of payer interventions (e.g., ASP conversion, utilization scrutiny).
• Assessment of practice financial dependency on drug margins.

Main Results:

• Payer interventions significantly reduced drug margins starting in 2005.
• Practices experienced substantial financial decline, with drug margins decreasing over 30% since 2002.
• Despite risks, practices remain dependent on drug margins for financial stability.

Conclusions:

• Practices are at risk of making poor financial decisions due to drug margin dependency.
• A "drug test" for practice financials is proposed to assess financial health without drug revenue.
• Practices must adjust service lines and salaries based on their level of dependency to ensure financial health.